中文
Press Release
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
Aug 20, 2021
Mabwell Receives IND Clearance from FDA for Initiating Clinical Trials for its Anti-CD47/PD-L1 Bispecific Antibody

➞
Aug 10, 2021
NMPA Accepted IND Application of China's First Anti-Nectin-4 ADC Drug

➞
Aug 02, 2021
Mabwell Was Included in the "List of New and Innovative Chinese Pharmaceutical Forces 2021"

➞
Jul 21, 2021
Mabwell's Anti-CD47/PD-L1 Bispecific Antibody 6MW3211 Receives IND Approval in China

➞
Jul 20, 2021
Activity Review | Harmony and Advancement, Deep Cultivation and Empowerment - Mabwell The 4th Science & Technology Conference

➞
Jul 09, 2021
Mabwell and Fudan University Shanghai Cancer Center Announce Strategic Cooperation

➞
Jul 08, 2021
Mabwell was included into the 2021 Chinese Pharmaceutical Talent Brand

➞
Jul 02, 2021
Mabwell awarded the certificate of Recognised Employer of CPA Australia

➞
Jun 04, 2021
Nature Index 2021 Annual Tables: Mabwell Ranks in the Top 10 Chinese Institutions in Life Sciences for the First Time

➞
May 27, 2021
Mabwell and Yangtze River Pharmaceutical Reached Strategic Cooperation on the Rights and Interests of Two Innovative Biologics in China

➞
Previous1 2 3 Next